title: Healing of Helicobacter pylori gastric ulcers: only eradication matters.
abstract: BACKGROUND
  some authors suggest that Helicobacter pylori eradication favors gastric ulcer healing.
  
  
  OBJECTIVE
  to study which factors influence ulcer healing in patients suffering from gastric ulcer with H. pylori infection.
  
  
  METHODS
  a prospective study of 230 patients with gastric ulcer associated to H. pylori infection. Chronic ingestion of non-steroidal anti-inflammatory drugs was considered as an exclusion. In an initial endoscopy, malignancy was histologically excluded and two biopsies each of antrum and body were obtained. Also, ELISA IgG serology and a 13C-urea breath test were performed. Eradication therapy with omeprazole (20 mg twice a day), clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day) was administered for seven days, followed by omeprazole 20 mg once a day for five more weeks. Endoscopy was repeated after 6 weeks of treatment and breath test was repeated 2 month after completing therapy.
  
  
  RESULTS
  overall gastric ulcer healing was achieved in 80.8% (95% CI: 75-85%) of cases by intention-to-treat, and in 82.6% (77-87%) per protocol. Ulcer healing was achieved in 94.3% (90-97%) of patients with eradication success, but only in 40.8% (28-54%) of patients with eradication failure (p<0.0001). In the multivariate analysis, H. pylori eradication was the only variable that correlated with ulcer healing (odds ratio 24; 95% CI: 10-56; p<0.0001) (x2 model: 64.4; p<0.0001). Additional variables (age, sex, sporadic ingestion of NSAIDs, smoking, previous ulcer disease, ulcer size and location) were not related to healing.
  
  
  CONCLUSIONS
  H. pylori eradication favors ulcer healing in patients with gastric ulcer, which is an argument in favor of the etiological role of the microorganism in this disease. Other factors did not influence ulcer healing.
authors.affiliation: Servicio de Gastroenterología. Hospital Ramón y Cajal. Universidad de Alcalá. Madrid. Spain. fbermejos@medynet.com
authors.forename: F
authors.initials: F
authors.lastname: Bermejo
authors.forename: D
authors.initials: D
authors.lastname: Boixeda
authors.forename: C
authors.initials: C
authors.lastname: Martín De Argila
authors.forename: A
authors.initials: A
authors.lastname: López San Román
authors.forename: V
authors.initials: V
authors.lastname: Defarges
authors.forename: H
authors.initials: H
authors.lastname: Hernández Ranz
authors.forename: M
authors.initials: M
authors.lastname: Vázquez
authors.forename: A
authors.initials: A
authors.lastname: García Plaza
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D011446:Prospective Studies; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents